Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 42, 2012 - Issue 6
419
Views
11
CrossRef citations to date
0
Altmetric
General Xenobiochemistry

Effect of a traditional Chinese medicine Liu Wei Di Huang Wan on the activities of CYP2C19, CYP2D6 and CYP3A4 in healthy volunteers

, , , , , & show all
Pages 596-602 | Received 12 Oct 2011, Accepted 23 Nov 2011, Published online: 30 Dec 2011
 

Abstract

  1. Liu Wei Di Huang Wan (LDW), a well-known traditional Chinese medicine, is widely used for the treatment of various diseases in China. This study was designed to investigate the potential herb–drug interactions of LDW in healthy volunteers and attempted to ascertain whether the interaction might be affected by genotypes.

  2. We assessed the effect of LDW on the activities of CYP2C19, CYP2D6 and CYP3A4 in 12 Chinese healthy subjects in a single-center, controlled, non-blinded, two-way crossover clinical trial. The subject pool consisted of six extensive metabolizers with CYP2C19*1/*1 and six poor metabolizers with CYP2C19*2/*2. Placebo or 4.8 g LDW (12 pills, 0.2 g/pill, twice daily) was given to each participant for 14 continuous days with a wash-out period of 2 weeks after an oral administration of 30 mg omeprazole, 30 mg dextromethorphan hydrobromide and 7.5 mg midazolam. The activities of CYP2C19, CYP2D6 and CYP3A4 were ascertained by their respective plasma or urinary metabolic ratios on day 14 post-treatment.

  3. There is no difference in the activities of the three tested enzymes before or after a 14-day administration of LDW. LDW had no effect on the pharmacokinetic parameters of the substrates and their metabolites.

  4. A 14-day administration of LDW did not affect the activities of CYP2C19, CYP2D6 and CYP3A4. LDW is unlikely to cause pharmacokinetic interaction when it is combined with other medications predominantly metabolized by these enzymes.

Acknowledgments

We thank the Basic Science Research Fund in CSU (No. 2010QZZD010), Huge Project to Boost Chinese Drug Development (No. 2011ZX09302), National Sci-Tech Support Plan of China (SQ2010BAJY1411-08), National Development of Key Novel Drugs for Special Projects of China (2011ZX09302) and Young Teachers Boost Plans of Chinese Central College (grant #201012200047) for financial support. We thank Dr. Shousong Cao of Roswell Park Cancer Institute (Buffalo, New York) and Visiting Professor of Central South University and Ms Zhuoran Duan for proof reading of the manuscript.

Declaration of interest

Financial support was provided by The Basic Science Research Fund in CSU (No. 2010QZZD010), Huge Project to Boost Chinese Drug Development (No. 2011ZX09302), National Sci-Tech Support Plan of China (SQ2010BAJY1411-08), National Development of Key Novel Drugs for Special Projects of China (2011ZX09302) and Young Teachers Boost Plans of Chinese Central College (grant #201012200047).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.